Print Page   |   Contact Us   |   Sign In   |   Register
News & Press: Regulatory Updates

PHSS May Regulatory Update: Noval Therapies; OBERA; When is a REMS Neccessary

14 May 2019  
Posted by: Tamsin Marshall
Share |

PHSS Regulatory Update May 2019  available for download for members! Login to view

 

During the last 4 weeks there have been a number of developments in the regulation of the pharmaceutical industry. This month reported issues have come from the EU Australian and USA regulatory authorities.

The topics covered in this edition of the “Update” include

 

Europe

  • The role of regulators in establishing added benefit of novel therapies
  • MHRA - GDP Office Based Evaluation and Risk Assessment programme (OBERA)

 

USA

 

  • Application of statutory factors in determining when a REMS is necessary
  • Bispecific antibody development programs
  • CBER FY 2018 Report
  • FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan
  • Special 301 Report on Intellectual Property Protection and Review of Notorius Markets for Piracy and Counterfeiting

 

International

Australia

  • Guidance for TGO 101 – (Standard for tablets, capsules and pills
  • Standard for Disinfectants and Sterilants (TGO 54 / TGO 104). - Outcomes from consultation

 

Products

  • Extending Expiration Dates of Doxycycline Tablets and Capsules in Strategic USA Stockpiles 

Membership Software Powered by YourMembership  ::  Legal